Thalassemia

Thalassemias are inherited blood disorders characterized by decreased hemoglobin production. Symptoms depend on the type and can vary from none to severe. Often there is mild to severe anemia. Anemia can result in feeling tired and pale skin. There may also be bone problems, an enlarged spleen, yellowish skin, and dark urine. Slow growth may occur in children. Thalassemias are genetic disorders inherited from a person's parents. There are two main types, alpha thalassemia and beta thalassemia. The severity of alpha and beta thalassemia depends on how many of the four genes for alpha globin or two genes for beta globin are missing. Diagnosis is typically by blood tests including a complete blood count, special hemoglobin tests, and genetic tests. Diagnosis may occur before birth through prenatal testing. Treatment depends on the type and severity. Treatment for those with more severe disease often includes regular blood transfusions, iron chelation, and folic acid.

https://en.wikipedia.org/wiki/Thalassemia

New Data From First Human Crispr Trials Shows Promising Results

Results from clinical trials released Tuesday indicate that two patients, one with beta thalassemia...

discovered 4 months ago on Forbes
CRISPR-based gene editing treatments benefit patients with blood disorders

The first two patients to receive CRISPR-based treatments for their blood disorders benefited from...

discovered 4 months ago on Axios
CRISPR gene-editing treatment shows success in first human patients

An investigational therapy using the revolutionary gene-editing technology CRISPR has shown...

discovered 4 months ago on CNET
Is Amarin's Fish Oil Pill on Track to Become a Blockbuster? | The Motley Fool

Meanwhile, shares in CRISPR Therapeutics (NASDAQ:CRSP) and partner Vertex Pharmaceuticals (NASDAQ:VRTX) are also soaring following the release of interim, early-stage results for its gene-editing ...

discovered 4 months ago on The Motley Fool
Crispr Therapeutics Stock Spikes on Positive Gene-Editing Results

Shares of Vertex Pharmaceuticals (ticker: VRTX), which partnered with the far smaller Crispr (CRSP)...

discovered 4 months ago on Barron s Online
Companies declare signs of success in CRISPR treatment of blood disorders

The era of editing human genes to treat inherited disease has arrived. The patients: One has...

discovered 4 months ago on Technology Review
Early Results Are Positive for Experimental CRISPR Therapies

Two clinical trial participants—one with β-thalassemia and one with sickle cell disease—appeared to...

discovered 4 months ago on The Scientist
CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients...

...2019 (GLOBE NEWSWIRE via COMTEX) -- -Two patients treated with CTX001 successfully engrafted and demonstrated an initial safety profile consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell transplant- -Beta thalassemia: Patient is transfusion independent with...

discovered 4 months ago on Market Watch
Crispr Surges as Gene Editing Shows Promise in Blood Disease

Crispr Therapeutics AG and Vertex said a pair of patients -- one suffering from beta thalassemia and...

discovered 4 months ago on Bloomberg
Editas Medicine Announces Third Quarter 2019 Results and Update

Corporate Upcoming Events Editas Medicine will participate in the following investor events: Editas Medicine will present pre-clinical data for EDIT-301 to address sickle cell disease and beta ...

discovered 4 months ago on Market Watch
U.S. FDA Approves Celgene's Rare Blood Disorder Drug

Reblozyl (luspatercept–aamt), which has been jointly developed by Celgene and Acceleron Pharma Inc, is meant for treatment of anemia in patients with beta thalassemia, who require regular red blood cell transfusions.

discovered 4 months ago on Medscape
The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and...

discovered 4 months ago on Zacks via Yahoo Finance
Why Celgene's Latest FDA Approval Makes Bristol-Myers Squibb's Dividend Look Even Better | The...

Celgene (NASDAQ:CELG) just announced a key regulatory approval that should boost BMS' fortunes. On...

discovered 4 months ago on The Motley Fool
Stem Cell Banking Market : Facts, Figures and Analytical Insights 2018 - 2024

Nearly 500 stem cell banks are functioning globally, and every bank is now striving harder to increase their market share. Stem cell banking has applications in cerebral palsy, thalassemia ...

discovered 4 months ago on Market Watch
Sickle Cell Disease Therapeutics Market 2019-2026 | Focuses on the Global Key Manufacturers,...

Segment by Regions North America Europe China Japan Segment by Type Sickle Cell Anemia Sickle Beta Thalassemia Sickle Hemoglobin C Disease Segment by Application Hospitals ...

discovered 4 months ago on Market Watch
Blood drive for Connecticut siblings with rare genetic blood disorder

Daniela and Matteo Ciriello are living with a rare genetic blood disorder called Beta Thalassemia or...

discovered 4 months ago on WTNH-TV New Haven
Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted...

CTX001 is currently being evaluated in two ongoing Phase 1/2 studies in patients with transfusion-dependent beta thalassemia and severe sickle cell disease, where a hematopoietic ...

discovered 4 months ago on Market Watch
The FDA approves "orphan drug" treatment for rare inherited anemia

Food and Drug Administration (FDA). The drug, called Reblozyl, has been approved to treat an...

discovered 4 months ago on Newsweek
Alpha Thalassemia Market Growth, Share, Trends and Forecasts 2019-2026

Nov 13, 2019 (Global QYResearch via COMTEX) -- The report on Global Alpha Thalassemia Market is the latest addition to the huge database of Ameco Research. This research study ...

discovered 4 months ago on Market Watch
4 Biotech Stocks That Could Keep Beating Wall Street

Earlier this month, the drugmaker’s rare disease drug Reblozyl was approved by the FDA. Reblozyl treats anemia in patients with beta thalassemia, a rare...

discovered 4 months ago on Zacks via Yahoo Finance
Edited Transcript of XLRN earnings conference call or presentation 6-Nov-19 3:00pm GMT

Beginning with luspatercept, the U.S. FDA and the European Medicines Agency are currently reviewing the BLA and MAA filings respectively for the treatment of anemia in adult patients with beta ...

discovered 4 months ago on Thomson Reuters StreetEvents via Yahoo Finance
...® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require...

SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 8, 2019--

discovered 4 months ago on Olean Times Herald
Acceleron Announces Luspatercept Presentations at the 61st American Society of Hematology Annual...

“It’s a privilege to return to the world’s largest hematology meeting to share updated results from the Phase 3 trials of luspatercept in patients with myelodysplastic syndromes and beta-< ...

discovered 4 months ago on Market Watch
Protagonist Therapeutics Reports Third Quarter 2019 Financial Results

"These maturing assets reflect our steady transition toward becoming a fully integrated company. In addition to the ongoing Phase 2 study in beta-thalassemia, we continue ...

discovered 4 months ago on Market Watch
FDA Approves Celegene's Reblozyl To Treat An Inherited Blood Disorder

The U.S. Food and Drug Administration approved the first therapy for patients with a rare inherited...

discovered 4 months ago on RTT News
Acceleron Reports Third Quarter 2019 Operating and Financial Results

“With the FDA’s decision on the luspatercept regulatory submission for the treatment of beta-thalassemia expected in less than one month, we are close to achieving a major ...

discovered 4 months ago on Market Watch
bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of...

bluebird bio, Inc. BLUE, +2.66% announced today that new and updated data from its investigational gene and cell therapy programs for multiple myeloma, sickle cell disease (SCD) and transfusion-dependent ...

discovered 4 months ago on Market Watch
FDA approves first therapy to treat patients with rare blood disorder

Food and Drug Administration granted approval to Reblozyl (luspatercept–aamt) for the treatment of...

discovered 4 months ago on PR Newswire via Yahoo Finance
Celgene & Acceleron Get FDA Nod for Rare Blood Disorder Drug

Corporation CELG and partner Acceleron Pharma Inc. XLRN announced that the FDA has approved pipeline...

discovered 4 months ago on Zacks via Yahoo Finance